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infections. However, intravenous administration in patients with SMID may be difﬁcult because of
insufﬁcient vascular development.
Objectives: The aim of our study was to determine the feasibility of subcutaneous drug administration by
mentholated warm compresses (WMCs) as an alternative delivery method for ceftazidime in patients
with SMID.
Methods: CAZ was subcutaneously administered to the abdominal region of naphazoline-treated
hypoperfused guinea pigs, which were used as a hemodynamic model of patients with SMID. MWCs
or warm compresses (WCs) were applied to the injection site to increase blood ﬂow. We calculated the
cumulative CAZ absorption over time by using the deconvolution method.
Results: Application of MWCs or WCs increased blood ﬂow at the administration site and increased CAZ
plasma levels. Application of MWCs or WCs after subcutaneous CAZ injection led to higher CAZ plasma
levels than the mutant prevention concentration for a longer period than was observed for CAZ
administration without the application of MWCs or WCs.
Conclusions: The application of MWCs or WCs enhanced subcutaneous CAZ absorption by increasing
blood ﬂow. MWCs and WCs are considered to be safe and routine methods to induce defecation after
surgery on the digestive system; thus, the combination of these methods and subcutaneous CAZ
administration is a potential method for treating pneumonia in patients with SMID.
& 2014. The Authoes. Published by Elsevier Inc. This is an open access article under the CC BY-NC-SA
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).Introduction
People with severe motor and intellectual disabilities (SMIDs)
exhibit abnormal muscle tone, dysfunctional swallowing, and
respiratory and gastrointestinal disorders.1 Inhalation of saliva
and vomiting leads to the development of pathogenic bacteria in
the respiratory system, causing repetitive or chronic respiratory
infections.2 The most common cause of death in patients with
SMID is aspiration pneumonia.3,4
The preferred treatments for aspiration pneumonia are admin-
istration of a third-generation cephalosporin or penicillin combinedr Inc. This is an open access article
hD, Department of Analytical
ical Sciences, Josai University,with a β-lactamase inhibitor. A survey of antibiotic use at the
National Rehabilitation Center for Children with Disabilities
(between April 1, 2008, and March 31, 2009) found that frequently
used antibiotics were the penicillin-based piperacillin sodium and
ceftazidime (CAZ), a third-generation cephalosporin. The Japanese
Association for Infectious Diseases/Japanese Society of Chemother-
apy Guidelines for the Treatment of Infectious Diseases: Respiratory
Infections also state that the treatment of hospital-acquired aspira-
tion pneumonia should cover gram-negative rod bacteria, including
Pseudomonas aeruginosa, and CAZ covers a wider range of gram-
negative rod bacteria than does piperacillin sodium.5 The efﬁcacy of
CAZ is determined by the time during which CAZ blood concen-
trations exceed the MIC of the drug to inhibit the growth of wild-
type bacteria.6 Moreover, to prevent the occurrence of CAZ-resistant
bacteria, it is necessary to consider the mutant prevention concen-
tration (MPC) in addition to the MIC.7under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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time during which their movements are limited.8 In these
people, vascular development may be insufﬁcient, and blood
vessels of sufﬁcient thickness may be difﬁcult to target for
intravenous administration of CAZ for pneumonia treatment. It
is necessary to consider alternative administration routes that
can be used simply and reliably, and thus we focused on the
subcutaneous route of administration for the treatment of
pneumonia with CAZ in patients with hypoperfusion. This route
of administration is simpler than the intravenous route, and
reduces the incidence of peripheral phlebitis and systemic
infections.9
Patients with SMID often experience symptoms caused by
disturbances in the autonomic nervous system.10,11 In particular,
skin blood ﬂow may be reduced by constriction of the skin blood
vessels due to elevated sympathetic nervous system tone.12 Sub-
cutaneous blood ﬂow may be slower in patients with severe
disabilities compared with healthy individuals; therefore, low drug
absorption rates due to limited blood ﬂow, which lead to sub-MIC
or sub-MPC blood levels, must be considered when treating such
patients.
We have previously reported13 that reduced cutaneous blood
ﬂow decreased skin permeation of nicardipine hydrochloride, and
that the addition of a strong permeation enhancer that had been
screened in vitro to the formulation most likely caused the
observed decrease in cutaneous blood ﬂow. Thus, it is important
that methods that promote absorption increase blood ﬂow at the
site of drug administration.
Hot compresses applied locally to the site of drug administra-
tion have been shown to increase local subcutaneous blood ﬂow
through vasodilation.14 Mentholated warm compresses (MWCs)
and warm compresses (WCs) are used widely in clinical settings to
induce defecation after gastrointestinal tract surgery, and their
safety is well established.15–17
In our study we investigated the use of MWC and WC
methods to enhance the absorption of subcutaneously admin-
istered drugs with the goal of reaching blood levels that exceed
the MIC and MPC in patients with hypoperfusion. The vaso-
constrictor naphazoline was used to produce hypoperfusion in
guinea pigs as a model of reduced blood ﬂow in patients with
SMID.1860 Saline
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Figure 1. Blood ﬂow changes in hypoperfused guinea pigs. Guinea pigs received an i
naphazoline as a vasoconstrictor, 150 minutes after anesthesia. Blood ﬂow was measured
¼ 8; 0.15 mg/kg naphazoline group, n ¼ 4; 1.5 mg/kg naphazoline group, n ¼ 4). *P oMethods
Materials
Naphazoline nitrate was purchased from Wako Pure Chemical
Industries (Osaka, Japan). Ceftazidime was obtained from Glax-
oSmithKline Co Ltd (Tokyo, Japan). Cephalexin hydrate (CEX)
was purchased from Sigma Chemical Co Ltd (St Louis, Missouri).
Mentha oil was acquired from Yoshida Pharmaceutical Co Ltd
(Saitama, Japan). All other chemicals and solvents were of rea-
gent grade or HPLC grade and used without further puriﬁcation.Animals
Male Hartley guinea pigs (Japan SLC, Shizuoka, Japan) of
identical age (7 weeks, 450–500 g; n ¼ 42) were reared under
constant temperature (221C 721C) and humidity (55% 7 5%),
with a 12-hour light cycle from 7 AM to 7 PM. Feed and water were
supplied ad libitum. All experiments using animals were approved
by the Institutional Animal Care and Use Committee of Josai
University (approval No. H22043-2010/05/14).Blood ﬂow measurement using laser Doppler ﬂowmetry
Guinea pigs were anesthetized with urethane (1.5 g/kg IP), and
blood ﬂow in the abdominal region was measured using a laser
Doppler ﬂow meter (Peri Flux PF3; Perimed KB Co, Lund, Swe-
den).13 Animals were divided into 3 groups (saline group, n ¼ 8;
naphazoline group, n ¼ 4 each). A 0.15 or 1.5 mg/kg dose of
naphazoline was administered to guinea pigs to induce hypoper-
fusion. Control animals received a physiologic saline solution
injection into the femoral muscle. The laser Doppler probe
(6 mm diameter; Perimed KB Co) was attached to the shaved
abdominal skin, and blood ﬂow was measured for 6 hours. Blood
ﬂow was measured every 5 seconds for 3 minutes, and the mean
of these measurements was used for each blood ﬂow value. The
data are represented as changes in blood ﬂow (ie, percent of
initial ﬂow).g/kg naphazoline
/kg naphazoline
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every 10 minutes for 6 hours. Each point represents the mean (SD) (saline group, n
0.05 (0.15 mg/kg vs. saline). #P o 0.05 (1.5 mg/kg vs saline).
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Figure 2. Plasma concentration-time curves after intravenous injection of
(A) ceftazidime (CAZ) and (B) cephalexin hydrate (CEX), following intravenous
injection of saline or naphazoline into the jugular vein. Each point represents the
mean (SD) (saline group, n ¼ 3; 1.5 mg/kg naphazoline group, n ¼ 5). The solid line
indicates the model ﬁt using a 2-compartment model.
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Animals were divided into 2 groups (saline group, n ¼ 3; 1.5 mg/kg
naphazoline group, n ¼ 5). Immediately after the intramuscular
administration of naphazoline (1.5 mg/kg) or saline (as a control),
CAZ (17 mg/kg) and CEX (7 mg/kg) were injected into the jugular vein.
The dose of 17 mg/kg represents the converted clinical dose
(1 g/administration for a 60-kg adult). Blood samples (0.25 mL) were
taken from the contralateral jugular vein at different time intervals (5,
10, 15, 20, 40, 60, 90, 120, 240, and 360 minutes) for 6 hours, and
immediately centrifuged (41C; 3000 g; 10 minutes) to collect plasma,
which was stored at –451C until the analysis. Heparin sodium (5 U/mL)
was used as an anticoagulant for plasma sampling. The plasma
concentration-time proﬁle of CAZ and CEX were analyzed by2-compartment model, where the plasma concentrations after intra-
venous administration are described as follows:
CðtÞ ¼ DðαK21Þ
V1ðαβÞ
eαtþ DðK21βÞ
V1ðαβÞ
eβt ð1Þ
where α and β are constants, V1 is the volume of drug within the
central compartment, V2 is the volume of drug within the periph-
eral compartment, K21 is the migration rate constant for migration
from the peripheral to central compartment, K12 is the migration
rate constant for migration from the central to peripheral compart-
ment, K10 is the elimination rate constant for elimination from the
central compartment, and CLtot is the total body clearance.
The value of α, β, V1, and K21 were estimated by ﬁtting
the above equation 1 to the concentration-time curve after intra-
venous administration using MULTI to the nonlinear least-squares
method (algorithm; Gauss-Newton method).19 The values
obtained for α, β, V1, and K21 were used in equations 2 to 7 to
calculate the other parameters.
t1=2α ¼
0:693
α
ð2Þ
t1=2β ¼
0:693
β
ð3Þ
V2 ¼
K12UV1
K21
ð4Þ
K12 ¼ αþβK21K10 ð5Þ
K10 ¼
αβ
K21
ð6Þ
CLtot ¼
Dαβ
Aβ þ Bα ð7Þ
Subcutaneous administration of CAZ to hypoperfused guinea pigs
Animals were divided into 4 groups (n ¼ 3 each) according to
the dose level, and injection volume. CEX, which has a high urinary
excretion rate, was coadministered with CAZ to correct a decrease in
the elimination rate of CAZ in naphazoline-treated animals. Guinea
pigs were anesthetized by intraperitoneal administration of ure-
thane (1.5 g/kg). Naphazoline saline solution (1.5 mg/kg) was
injected into the femoral muscle to reduce blood ﬂow 2.5 hours
after anesthesia administration. Intravenous administration of a CEX
saline solution (7 mg/kg) in the jugular vein immediately followed.
A CAZ saline solution (17 mg/320 μL [1D1V], 17 mg/640 μL [1D2V],
34 mg/320 μL [2D1V], or 34 mg/640 μL [2D2V]) was subcutaneously
administered over a 30-minute period at 2 sites in the abdominal
region. After CAZ administration, blood samples (0.25 mL) were
taken from the contralateral jugular vein at predetermined times
(0, 5, 10, 15, 20, 40, 60, 90, 120, 180, 240, 300, and 360 minutes) for
6 hours and immediately centrifuged to collect plasma. The super-
natant was 1 stored at –451C until analysis, in which plasma
concentrations of CAZ and CEX were determined using an HPLC
system. In addition, the blood ﬂow at the administration sites was
measured using a laser Doppler ﬂow meter.
Effect of the mentholated warm compress on CAZ subcutaneous
absorption
Animals were divided into 3 groups (n ¼ 3 each). To prepare an
MWC, mentha oil (0.5 mL) was dripped into warm tap water (651C;
500 mL) to prepare saturated mentha water.20 The MWC consisted
of a towel (11  33 cm) that was soaked in saturated mentha water
until its temperature reached 651C. The administration site was
covered with the MWCs immediately after CAZ administration, and
Table I
Pharmacokinetic parameters of ceftazidime (CAZ) and cephalexin hydrate (CEX) in hypoperfused guinea pigs after intravenous administration.
CAZ CEX
Parameter Without naphazoline With naphazoline Without naphazoline With naphazoline
α*, 1/h 1.87 7 0.97 4.02 7 1.62 8.75 7 2.88 4.41 7 1.25
β*, 1/h 0.29 7 0.12 0.07 7 0.05 0.15 7 0.12 0.08 7 0.06
t1/2α, h 0.20 7 0.15 0.18 7 0.09 0.08 7 0.03 0.15 7 0.05
t1/2β, h 1.81 7 0.64 13.05 7 9.13 4.95 7 1.46 8.97 7 3.15
V1†, mL 157.94 7 9.20 86.64 7 11.58 149.49 7 34.97 114.20 7 13.01
V2‡, mL 80.83 7 22.13 139.95 7 62.24 674.66 7 287.87 231.44 7 22.10
K21§, 1/h 1.06 7 0.78 1.59 7 0.70 1.59 7 0.65 1.38 7 0.48
K12||, 1/h 1.76 7 1.28 2.84 7 1.66 6.60 7 2.28 3.19 7 0.62
K10¶, 1/h 0.70 7 0.20 0.19 7 0.09 0.83 7 0.03 0.31 7 0.20
CLtot#, L/h 0.10 7 0.03 0.02 7 0.01 0.13 7 0.03 0.03 7 0.02
n Constants.
† Volume of drug within the central compartment.
‡ Volume of drug within the peripheral compartment.
§ Migration rate constant for migration from the peripheral to central compartment.
|| Migration rate constant for migration from the central to peripheral compartment.
¶ Elimination rate constant for elimination from the central compartment.
# Total body clearance.
T. Ebihara et al. / Current Therapeutic Research 77 (2015) 7–1310the MWCs were entirely covered with plastic cling wrap to prevent
mentha water evaporation. WCs that did not contain mentha
oil were similarly applied to the administration site.
In addition, the abdomen was wrapped with a towel. The MWCs
or WCs were replaced every 30 minutes, and they were replaced a
total of 13 times during the duration of the experiment. To ensure
that the mentha water saturation of the administration site was
maintained, mentha oil was added 5 minutes before the MWCs were
changed.
HPLC separation and quantiﬁcation of CAZ and CEX
A 7.0% (vol) perchloric acid solution (100 μL) was added to each
plasma sample (100 μL), and this mixture was centrifuged for 15
minutes (41C; 13,000 g). The supernatant (20 μL) was injected into
the HPLC system to determine CAZ and CEX plasma concentrations.
The HPLC system consisted of a pump (LC-10ATvp; Shimadzu
Corp, Kyoto, Japan), a degasser (DGU-12A; Shimadzu Corp), a
column oven (CTO-10Avp; Shimadzu Corp), a column (TSK-gel
ODS-80TM, 5 μm, 4.6  250 mm; TOSOH Corp, Tokyo, Japan), and
an ultraviolet detector (SPD-6A; Shimadzu Corp). A mobile phase
consisting of 9:91 (v/v) acetonitrile:10 mM phosphate buffer (pH
3.0) was used for elution. The ﬂow rate was 1.0 mL/min, the
column temperature was 501C, and the detector operated at a
wavelength of 258 nm.
Under the HPLC condition for the analysis of CAZ, the peaks of
CAZ and CEX appeared on the chromatogram of the ultraviolet
detector at 8.8 and 15.8 minutes, respectively. From the standard
deviation of the response and the slope of the calibration line, the
detection limit for CAZ was calculated to be 0.02 μg/mL, whereas
the detection limit for CEX was 0.05 μg/mL. Similarly, the lower
limit of quantiﬁcation for CAZ was calculated to be 0.06 μg/mL,
whereas that of CEX was 0.13 μg/mL. A calibration line was
produced every time the HPLC pump was stopped.
Estimation of CAZ absorption rate by the deconvolution method
The deconvolution method was used to estimate subcutaneous
CAZ absorption rates (Research Institute of TTS Technology, Sai-
tama, Japan).21 The time course of the subcutaneous absorption
rate, I(θ), was estimated from the time course of the blood
concentration after subcutaneous (C[t]) and intravenous (W[t])
administrations. C(t) is the response function, W(t) is the weight
function, and I(θ) is the input function.21,22 C(t) is expressed asfollows:
C tð Þ ¼
Z t
0
Wðt–θÞUIðθÞUdθ ð8Þ
The volume of distribution of CAZ and its elimination rate
constant were decreased by naphazoline-induced hypoperfusion;
thus, correction of the weighting function was necessary to
estimate the absorption rate of CAZ. Ratios comparing the phar-
macokinetic parameters of CEX in hypoperfused guinea pigs and
normal guinea pigs were determined. The pharmacokinetic
parameters of CAZ in normal guinea pigs were multiplied by these
ratios to estimate the pharmacokinetic parameters of CAZ in
hypoperfused guinea pigs. Using these parameters as weighting
functions, and the CAZ plasma level-time curve after subcutaneous
administration in hypoperfused guinea pigs as a response function,
the time-course of cumulative CAZ absorption was estimated using
the deconvolution method. The average absorption rate was used
to compare the absorption rates between administration methods.
The average absorption rate is the slope of the cumulative
absorption proﬁle.23
Statistical analysis
All data are presented as mean (SD). Differences in blood ﬂow
and plasma concentrations of CAZ among the groups were
analyzed using ANOVA. When an ANOVA showed a signiﬁcant
effect (P o 0.05), Tukey’s honest signiﬁcant difference test was
used as a post-hoc test to compare means, and differences were
considered to be signiﬁcant if the value of P was o0.05. All
analyses were conducted using software from the R Project for
Statistical Computing (R version 2.15.2, R Foundation for Statistical
Computing, Vienna, Austria).Results
Blood ﬂow measurement using laser Doppler ﬂowmetry in
hypoperfused guinea pigs
After administration of 0.15 and 1.5 mg/kg naphazoline, blood
ﬂow immediately decreased by 30% and 50%, respectively, compared
with baseline. The reduction of blood ﬂow caused by 1.5 mg/kg
naphazoline administration persisted until the end of the measure-
ment period (Figure 1).
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Figure 3. Plasma concentrations of ceftazidime (CAZ) and blood ﬂow changes after
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administration
The CAZ and CEX plasma concentration-time curve after intra-
venous CAZ and CEX administration following intramuscular
administration of naphazoline or saline is shown in Figure 2, and
the corresponding pharmacokinetic parameters are presented in
Table I.
The elimination of CAZ, determined using a 2-compartment model,
was signiﬁcantly altered, most likely due to a blood ﬂow reduction
after naphazoline administration, and had to be corrected to estimate
the subcutaneous absorption rate of CAZ. Thus, intravenous coadmi-
nistration of CEX, which has a high urinary excretion rate,24 was
performed at the same time as subcutaneous CAZ administration. The
elimination parameters of CAZ were then determined based on the
changes observed in the elimination parameters of CEX.
CAZ subcutaneous absorption proﬁle in hypoperfused guinea pigs
We hypothesized that CAZ blood levels would be approximately
equivalent after intravenous administration of identical doses per
time unit (eg, 17 mg for 1D1V and 1D2V or 34 mg for 2D1V and
2D2V). However, doubling the volume of vehicle (2V) resulted in
signiﬁcantly increased CAZ blood levels compared with the original
vehicle volume (1V) (Figure 3A). CAZ blood levels exceeded its
MIC90 (16 μg/mL) under all conditions of administration.25,26
However, in the 1D1V condition, CAZ blood levels did not exceeded
the MPC (32 μg/mL),27 which was exceeded in the other conditions.
Blood ﬂow changes occurring during CAZ subcutaneous admin-
istration are shown in Figure 3B. Blood ﬂow rapidly decreased
after naphazoline administration in all conditions, and then
reached a constant rate. No difference was observed among
groups. Figure 3C shows the CAZ cumulative absorption proﬁle
estimated using the deconvolution method. The subcutaneous
absorption of CAZ was not complete 6 hours after CAZ admin-
istration in the 1D1V and 2D1V groups, whereas almost all of the
administered CAZ was absorbed in the 1D2V and 2D2V groups.
Effect of WMCs on CAZ subcutaneous absorption in hypoperfused
guinea pigs
MWCs and WCs were applied to the 1D1V group. CAZ plasma
levels were markedly increased in both the MWC and WC groups
compared with the control group, and were approximately 4 and
6 times higher, respectively, than in the control group 6 hours after
administration (Figure 4A). Naphazoline administration resulted in
a blood ﬂow decrease, which was partially inhibited by the
application of an MWC or a WC (Figure 4B). Figure 4C shows the
cumulative CAZ absorption as estimated using the deconvolution
method. CAZ absorption after subcutaneous administration was
about 84.0% complete in the MWC group (14.1 mg absorbed) after
6 hours, whereas 60.0% of the administered CAZ was absorbed in
the WC group. The average absorption rate throughout the period of
experimentation was increased compared with the 1D1V group by
the application of WCs or MWCs (1D1V, 0.013 mg/min; with WC,
0.027 mg/min; with MWC, 0.039 mg/min). The increased absorp-
tion that was produced by application of an MWC or WC reached
levels equivalent to those of the 1D2V and 2D1V groups (Figure 3C).subcutaneous injection in hypoperfused guinea pigs. CAZ was administered
subcutaneously at a dose of 17 mg (1D) or 34 mg (2D) over a 30-minute time
period in different vehicle volumes (1V or 2V). (A) CAZ plasma concentration-time
curves. (B) Corresponding blood ﬂow changes. (C) Cumulative amounts of absorbed
CAZ as obtained by the deconvolution method. Each point represents the mean
(SD) (n ¼ 3). *P o 0.05 (1D2V vs 1D1V). #P o 0.05 (2D1V vs 1D1V). †P o 0.05
(2D2V vs 1D1V).Discussion
Abdominal subcutaneous blood ﬂow was reduced by intra-
muscular administration of naphazoline. In the 0.15 mg/kg
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Figure 4. Effects of mentholated warm compresses (MWCs) and warm compresses
(WCs) on cefazidime (CAZ) subcutaneous absorption in hypoperfused guinea pigs.
CAZ was administered subcutaneously at a dose of 17 mg (1D) over a 30-minute
time period (1D1V). (A) CAZ plasma concentration-time curves. (B) Blood ﬂow
changes. (C) Cumulative amounts of absorbed CAZ as obtained by the deconvolu-
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1D1V). #P o 0.05 (þMWC vs 1D1V).
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with the saline group was observed for only 2 hours after
administration. In contrast, naphazoline at a dose of 1.5 mg/kg
reduced abdominal subcutaneous blood ﬂow for 6 hours. The dose
of naphazoline used to produce hypoperfused guinea pigs was
therefore set at 1.5 mg/kg. Naphazoline administration decreased
the K10 (elimination rate constant) of CAZ (Table I). Because the
CAZ doses per unit of time were equivalent in the 1D1V and 1D2V
groups, as well as the 2D1V and 2D2V groups, we expected plasma
levels of CAZ to be equivalent within these pairs of treatment
groups. However, doubling the volume of vehicle resulted in
elevated CAZ levels. It has been previously reported that subcuta-
neously administered drugs spread horizontally in the subcuta-
neous tissue at the site of administration.28 Therefore this ﬁnding
may indicate that the subcutaneous area that came into contact
with CAZ was increased (Figure 3).
MWCs and WCs were applied to the injection site to alter local
blood ﬂow. MWCs and WCs are frequently used to promote
defecation by inducing intestinal peristalsis in clinical settings.15–17
Plasma CAZ concentrations were increased compared with those in
the control group by the application of MWCs and WCs to the
administration site. Reduced blood ﬂow due to naphazoline admin-
istration was shown to recover slightly due to MWC and WC
application.
In intermediate air temperatures, skin temperature increases as
skin blood ﬂow increases, because skin temperature is generally
dependent on skin blood ﬂow. Although differences in effects on skin
temperature between MWCs and WCs were not observed in our
study, different effects on skin and core body temperatures for these
treatments have been reported under a variety of conditions. More-
over, it has also been reported that MWCs elevated skin temperature
and body core temperature, and maintained elevated core body
temperature for signiﬁcantly longer than WCs.20 It is possible that
MWCs induced a greater absorption enhancement than WCs because
of their effects on deep blood ﬂow (Figure 4). The laser Doppler
ﬂowmetry probe measures ﬂow at the dermoepidermal interface,
where skin blood ﬂow is most abundant. It is not possible currently
to measure blood ﬂow that inﬂuences the absorption of drugs in
tissues deeper than the skin with this method.
Consideration of the MPC is advocated in addition to the MIC as
a means of preventing the occurrence of resistant bacteria. In
general, the growth of wild-type bacteria is prevented when the
concentration of antibiotics in the blood exceeds the MIC.
If mutant bacteria with acquired resistance coexist with wild-
type bacteria, then the mutant population will survive antibiotic
exposure at the MIC. However, as the concentration of antibiotics is
increased further, mutant bacteria are killed in addition to wild-
type bacteria. The concentration at which this effect occurs is
known as the MPC.7 In our study, a therapeutic effect equivalent to
that of intravenous administration was obtained by increasing the
dose of CAZ or vehicle volume per unit time. However, doubling the
vehicle volume might be clinically difﬁcult, because subcutaneous
administration rates 41 mL/min can be painful.9,29,30 On the other
hand, the application of WCs or MWCs to the site of CAZ subcuta-
neous administration may be expected to increase its therapeutic
effect without changing its infusion rate. Furthermore, this method
prevents the development of drug-resistant mutants, because CAZ
blood levels achieved through this method exceed the MPC.Conclusions
The subcutaneous administration of CAZ in combination with
MWCs or WCs is a potential alternative to intravenous CAZ
T. Ebihara et al. / Current Therapeutic Research 77 (2015) 7–13 13administration, and should be investigated clinically for the treat-
ment of pneumonia in patients with hypoperfusion associated
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